Virbac Unveils Canine Cephalexin Tablet

Posted: Sept. 5, 2012, 8:05 p.m. EDT



Published:

Virbac Animal Health of Fort Worth, Texas, launched the first chewable cephalexin tablet designed exclusively for dogs, the company reported Tuesday.

The FDA-approved drug, called Rilexine, is indicated for the treatment of secondary superficial bacterial pyoderma in dogs caused by susceptible strains of Staphylococcus pseudintermedius.

Previously, veterinarians often relied on the generic human form of cephalexin to treat dogs, but Rilexine is the first drug of its kind approved by the U.S. Food and Drug administration for the veterinary market, Virbac reported. The new drug should overcome some of the drawbacks of prescribing human cephalexin off-label, including a bitter, metallic taste and strong odor, a lack of veterinary-specific guidelines and the inability to tailor doses, Virbac noted.

Pyoderma is one of the most common diseases seen in dogs, and secondary superficial bacterial pyoderma is the most common form of pyoderma, according to Virbac.

Rilexine is available in 150 mg, 300 mg and 600 mg scored doses. The drug should not be prescribed to dogs that have a known allergy to cephalexin or the B-lactam group of antibiotics.

<HOME>

Archive »Read More

Study on Human Nails May Shed Light on Disease in the Hooves of Animals

The study, conducted by The University of Nottingham School of Veterinary Medicine and Science, found that excessive grooming of fingernails and toenails could lead to serious nail conditions, a finding that can be applied to farm animals and horses.

Ross University Gains International Partner

A Memorandum of Understanding signed by Ross University School of Veterinary Medicine and Ngee Ann Polytechnic in Singapore aim to develop mutually beneficial collaborations in education and research.

Purdue to Launch Residency Program in Vet Pharmacy

The program is co-sponsored by Purdue’s College of Veterinary Medicine and College of Pharmacy.

Add your comment:

Events


Show More...